GLYCOSYLATION PRODUCTS AS TOXIC MEDIATORS OF DIABETIC COMPLICATIONS

被引:75
作者
BROWNLEE, M
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461
[2] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIABET RES CTR,BRONX,NY 10461
来源
ANNUAL REVIEW OF MEDICINE | 1991年 / 42卷
关键词
DIABETES; EXTRACELLULAR MATRIX; MACROPHAGES; GROWTH FACTORS; COAGULATION; DNA; PHARMACOLOGY; THERAPY; AMINOGUANIDINE;
D O I
10.1146/annurev.med.42.1.159
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hyperglycemia causes excessive amounts of irreversible advanced glycosylation end products (AGEPs) to accumulate on long-lived extracellular matrix proteins and probably also on DNA in tissues that develop diabetic complications. AGEPs induce permanent abnormalities in extracellular protein cross-linking, cell-matrix interactions, and DNA structure in vitro. Pharmacologically inhibiting AGEP formation in long-term diabetic animals prevents both retinal capillary pathology and thickening of the glomerular basement membrane.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 32 条